WO1997015685A1 - NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION - Google Patents
NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION Download PDFInfo
- Publication number
- WO1997015685A1 WO1997015685A1 PCT/EP1996/004671 EP9604671W WO9715685A1 WO 1997015685 A1 WO1997015685 A1 WO 1997015685A1 EP 9604671 W EP9604671 W EP 9604671W WO 9715685 A1 WO9715685 A1 WO 9715685A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- prp
- rna
- acid molecules
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
Definitions
- the present invention celates to a process for the identification and isolation of nucleic acid molecules capable of distinguishing the isoforms PrP and PrP Sc of prion proteins as well as to the nucleic acid molecules obtainable by this process Furthermore, the invention relates to pharmaceutical and diagnostic compositions comprising said nucleic acid molecules
- TSEs transmissible spongiform encephalopathies
- BSE bovine spongiform encephalopathy
- TAE transmissible mine encephalopathy
- GSS Gerstmann-Straussler-Scheinker syndrome
- CJD Creutzfeldt-Jakob-Disease
- FFI fatal familial insomnia
- PrP Sc /PrP27-30 could convert the ubiquitous cellular isoform PrP c to PrP Sc /PrP27-30 It is assumed that chaperons may be involved in this process (Edenhofer et al 1996) PrP Sc /PrP27-30 could appear as a monomer (Prusiner 1982) or as a nucleation or crystal seed consisting of a PrP Sc /PrP27-30 oligomer (Lansbury and Caughey 1995) PrP c differs from PrP27-30 only with respect to its secondary structure the ⁇ -helical and ⁇ -sheet contents of PrP c are 42 % and 3 %, respectively (Pan et al , 1993) In contrast
- the technical problem underlying the present invention is to provide a process for the identification and isolation of molecules which are capable of distinguishing between the isoforms PrP c and PrP Sc or PrP27-30 of prion proteins and which are useful tools for diagnosis and therapy of transmissible spongiform encephalopathies
- the present invention relates to a process for the identification and isolation of nucleic acid molecules which are capable of distinguishing between the isoforms PrP c and PrP Sc or PrP27-30 of prion proteins associated with transmissible spongi ⁇ form encephalopathies comprising the steps of
- nucleic acids specifically recognizing a variety of protein targets including HIV-1 reverse transcriptase (Tuerk et al., 1992), HIV-1 Integrase (Allen et al., 1995), human ⁇ -thrombin (Kut ⁇ k et al., 1994) and Drosphila sex-lethal protein (Sakashita and Sakamoto, 1994).
- HIV-1 reverse transcriptase Tuerk et al., 1992
- HIV-1 Integrase Allen et al., 1995
- human ⁇ -thrombin Kert ⁇ k et al., 1994
- Drosphila sex-lethal protein Sakashita and Sakamoto, 1994.
- PrP c comprises the cellular isoform of the prion protein as well as fragments and derivatives thereof irrespective of the source organism.
- PrP Sc comprises the isoform of the prion protein associated with various transmissible spongiform encephalopathies. This term also comprises fragments of this prion protein isoform such as the truncated version of the isoform PrP Sc , the prion protein PrP27-30, which is the main component of prions. In particular, this term also includes PrP Sc proteins of the various Scrapie strains including those adapted to hamster, mouse or other vertebrates. Also included are derivatives of the prion protein isoform PrP Sc
- derivatives includes chemically modified versions of the prion protein isoforms PrP c and PrP Sc as well as mutants of these proteins, namely proteins which differ from the naturally occurring prion protein isoforms at one or more positions in the amino acid sequence, as well as proteins that show deletions or insertions in comparison to the naturally occurring prion protein isoforms. Such mutants can be produced by recombinant DNA technology or can be naturally occurring mutants.
- derivatives also embraces proteins which contain modified am o acids or which are modified by glycosylation, phosphorylation and the like.
- nucleic acid molecules single or double stranded nucleic acid molecules, such as RNA, modified RNA, single stranded DNA or double stranded DNA.
- a pool of nucleic acid molecules which constitutes the starting mate ⁇ al from which nucleic acid molecules are selected which specifically bind to one of the isoforms of the prion protein is defined as a mixture of nucleic acid molecules of different sequences
- This pool can be any mixture of nucleic acid molecules, preferably a pool of randomized molecules
- the nucleic acid molecules of the pool are chemically synthesized or produced by in vitro transcription
- RNA pool which is screened for molecules specifically binding to one of the isoforms of a prion protein is preferably the RNA pool M111 1 described in Famulok (1994) This pool consists of RNA molecules of 111 nucleotides randomized at 74 positions and results from the transcription of corresponding DNA sequences
- the pool M111 1 contains RNA molecules with approximately 1x10 15 different sequences
- the process according to the invention can be used to identify and isolate nucleic acid molecules which can distinguish between the two isoforms of prion proteins, PrP c and PrP Sc , associated with a transmissible spongiform encephalopathy such as Scrapie of sheep, bovine spongiform encephalopathy (BSE) of calf, transmissible mink encephalopathy (TME) of mink, Kuru, Gerstmann-Straussler-Scheinker Syndrome (GSS), fatal familial insomnia (FFI), Creutzfeldt-Jakob Disease (CJD) in the case of humans, chronic wasting disease (CWD) of mule, deer and elk or feline spongiform encephalopathy (FSE) of cats
- Transmissible spongiform encephalopathies are also known from nyala, gemsbok, arabian oryx, greater kudu, eland, ankole, moufflon, puma, che
- the step of incubating the pool of nucleic acid molecules with a prion protein can be carried out in different ways
- the protein is immobilized, for example, on a matrix such as a gel or a resm for chromatography
- a matrix such as a gel or a resm for chromatography
- the protein can be covalently linked to a matrix or can be bound to it by a specific interaction between a group present on the matrix and a domain of the protein specifically recognizing this group.
- a domain can be fused to a prion protein by recombinant DNA technology as will be discussed below.
- nucleic acid molecules which do not bind to the prion protein can be removed after incubation by washing with an appropriate buffer Subsequently the nucleic acid molecules binding to the prion protein can be eluted from the immobilized protein, for example by 8M urea, and further purified, for example, by phenol extraction and precipitation.
- the prion protein is in solution.
- the nucleic acid molecules binding to the prion protein can be isolated, for example, by carrying out a gel retardation assay and isolating the protein/nucleic acid complex. Subsequently the nucleic acid molecules can be isolated from the complex and further purified by known methods.
- the prion protein used in the process can be any of the known prion protein isoforms or a fragment or derivative of such a protein.
- the prion protein is the isoform PrP Sc present in the prion.
- the N-terminally truncated version of PrP Sc , PrP27-30 is used.
- PrP Sc and PrP 27-30 refer to any of these isoforms which can be found in an organism affected with a transmissible spongiform encephalopathy.
- the prion protein used in the process is the cellular isoform PrP c most preferably the processed form PrP c 23-231 which comprises ammo acids 23 to 231 of PrP c
- the prion protein used in the process is a recombinant protein This means that the protein is produced by recombinant DNA technology, namely by expression from a cloned DNA sequence
- the prion protein is part of a fusion protein
- a fusion protein can comprise beside the prion protein a protein or protein domain which confers to the fusion protein a specific binding capacity
- a domain may be an oligohistidme (Le-G ⁇ ce et al , 1990), Calmoduline binding peptide (CBP) (Carr et al , 1991 ), S-peptide (ribonuclease A) (Kim and Raines, 1993), FLAG (Kawase et al , 1995), green-fluorescent protein (GFP) (Hampton et al , 1996), BTag (Wang et al , 1996), or maltose-binding protein (MBP) (Aitken et al , 1994, Richards and Wyckoff, 1971 ) Proteins comprising such a domain can be immobilized for example, on IMAC- N ⁇ 2+ , Calmodulm, S-protein 104 aa (
- the isolated nucleic acid molecules are tested for their binding to the different isoforms, PrP c and PrP Sc , of a prion protein Those nucleic acid molecules are selected which specifically bind to only one of the isoforms
- the process according to the invention allows the identification and isolation of nucleic acid molecules which specifically bind to one of the isoforms of a prion protein or a fragment or derivative thereof and thereby allow the distinguishing of the different isoforms
- These nucleic acid molecules therefore show an unexpected high specificity, which is even higher than the specificity of poly- or monoclonal antibodies which cannot distinguish between the isoforms of prion proteins
- the process of the invention has been successfully carried out to isolate RNA molecules which can distinguish between the isoforms PrP c 23-231 and PrP27-30 from Syrian Golden Hamster
- the isoforms were recombinant proteins fused to glutathicne-s-transferase (GST PrP c 23-231 and GST rPrP27-30)
- the recombinant rPrP27-30 protein is identical in sequence to the natural PrP27-30 protein but reveals in contrast to the natural isoform proteinase K sensitivity
- nucleic acid molecules obtainable by a process according to the invention, namely to RNA, single stranded DNA or double stranded DNA molecules which bind to one of the isoforms of a prion protein
- nucleic acid molecules which specifically bind to the cellular isoform PrP c , namely to the processed form PrP c 23-231 , or specifically to the isoform PrP Sc , namely to the truncated version PrP27-30, or specifically to derivatives of these proteins
- nucleic acid molecules of the invention comprise four stretches of three consecutive guanosme residues separated by single stranded regions between four and seven nucleotides long More preferably, the nucleic acid molecules comprise a nucleotide sequence as depicted in SEQ ID NO 15, SEQ ID NO 16 or SEQ ID NO 17
- the region comprising the four guanosme stretches is flanked by two variable regions of predominantly Watson-Crick covariation
- the nucleic acid molecules preferably comprise a nucleotide sequence as depicted in any one of SEQ ID NO 1 to 13 and more preferably a nucleotide sequence as depicted in SEQ ID NO 18
- nucleic acid molecules according to the invention are further modified at one or more positions in order to increase their stability and/or to alter their biochemical and/or biophysical properties
- compositions comprising nucleic acid molecules according to the invention
- Such compositions can optionally comprise pharmaceutically acceptable carriers
- compositions may be useful for the therapy of transmissible spongiform encephalopathies such as those listed above. It may be possible, for example, to suppress the conversion of the isoform PrP c into the prion associated isoform PrP Sc by applying nucleic acid molecules which specifically bind to PrP c .
- the present invention relates to diagnostic compositions comprising nucleic acid molecules according to the invention.
- Such compositions may contain additives commonly used for diagnostic purposes.
- the nucleic acid molecules and the diagnostic compositions according to the invention can be used in methods for the diagnosis of transmissible spongiform encephalopathies.
- Such a method comprises, for example, the incubation of a probe taken from a body with at least one kind of nucleic acid molecules according to the invention and the subsequent determination of the interaction of the nucleic acid molecules with the isoforms PrP c and PrP Sc of a prion protein.
- nucleic acid molecule it is possible to use at least one kind of nucleic acid molecule according to the invention in order to quantitatively determine the amount of at least one isoform of a prion protein in a probe.
- nucleic acid molecules which specifically bind the PrP c isoform in combination with nucleic acid molecules which specifically bind the PrP Sc isoform in order to determine the absolute and/or relative amount of the isoforms in a probe.
- the probe may be obtained from various organs, perferably from tissue, for example, from brain, tonsils, ileum, cortex, dura mater, Purkinje cells, lymphnodes, nerve cells, spleen, muscle cells, placenta, pancreas, eyes, backbone marrow or peyer'sche plaques, for example in the form of thin sections
- tissue for example, from brain, tonsils, ileum, cortex, dura mater, Purkinje cells, lymphnodes, nerve cells, spleen, muscle cells, placenta, pancreas, eyes, backbone marrow or peyer'sche plaques, for example in the form of thin sections
- the probe may be obtained from a body fluid preferably from blood cerebrospinal fluid milk or semen
- brain biopsies can be performed on the alive organism
- the brain can originate from any organism that might be afflicted with a transmissible spongiform encephalopathy, such as sheep, calf, mice, cats, hamster, mule, deer, elk or humans or from other organisms which may be afflicted by a TSE as mentioned above
- the brain shoul originate from organisms which are PrP 00 (knock-out), PrP Sc (infected) and PrP c (wild-type) or of unknown PrP-status
- nucleic acid molecules according to the invention can be used to identify three dimensional structures which are necessary for the specific binding of a prion protein isoform With the help of this information other chemical compounds can be isolated or synthesized which can specifically bind prion protein isoforms
- the present invention also relates 4o chemical compounds other than nucleic acid molecules which are based on the information derived from a three dimensional structure of a nucleic acid molecule according to the invention, selected from the group consisting of inorganic or organic compounds, preferably sugars ammo acids, proteins or carbohydrates
- (r)PrP c stands for rPrP23-231
- rPrP27-30 stands for rPrP90-231 (Syrian Golden Hamster)
- Figure 1 B Illustrates schematically a further step in the in vitro selection of RNA molecules specifically binding to GST- rPrP c using GST rPrP c in solution and a gel retardation assay
- Figure 3 Shows the percentage of RNA binding to immobilized GST.. rPrP c 23- 231 after each cycle of the process described in Example 1. Radioactivity associated with GST::rPrP c beads after removal of the supernatant was set to 100 %. Radioactivity retained after 4 washing steps represents the percentage of RNA binding.
- Figure 4A Shows the binding of selected RNAs and unselected RNAs to GST, GST::rPrP e and GST:rPrP27-30. 5' labeled RNA was incubated in the presence of the proteins, filtered over BA85 nitrocellulose on a millipore slot blot apparatus. Retained radioactivity was quantified by Cerenkov counting.
- Figure 4B Shows that the in vitro selected RNA molecules of Example 1 distinguish between PrP c and rPrP27-30 from the Syrian Golden Hamster.
- Gel a 5' labeled RNA molecules after 9 cycles were incubated in the presence of GST, GST::PrP c and GST::rPrP27-30, and analyzed on 0.7 % non-denaturing agarose gels. Gels were fixed by 5 % TCA, dried and subjected to autoradiography. The GST :rPrP c /RNA complex from the 9th cycle was excised from the gel, the RNA extracted, reverse transcribed, PCR amplified and in vitro transcribed (see Figure 1B). This procedure was repeated twice for cycle 10 and 11.
- RNA aptamers directed against rPrP c 23-231 fused to GST from hamster by in vitro selection The aptamers belong to several groups of molecules RNA aptamers of group (A) (motif I) and (B) (motif II) can harbor G-quartet motifs and distinguish between rPrP23-231 (rPrP c ) and rPrP90-231 (rPrP27-30) RNA aptamers of group (C) (motif III) could also have G-quartet motifs but interact with rPrP23-231 (rPrP c ) and rPrP90-231 (rPrP27-30) (D) Aptamers with unique G-quartets
- RNA aptamers motif I and II distinguish the recombinant prion protein isoforms rPrP23-231 (rPrP c ) and rPrP90-231 (rPrP27-30) from hamster and calf
- A 4 pMols of labeled RNA Ap1 (motif I, lanes 1-3) were incubated in the presence of 40 pMols each of recombinant GST rPrP23-231 (rPrP c ) (lane 2) and GST rPrP90-231 (rPrP27-30) from Syrian golden hamster (lane 3)
- B 4 pMols of labeled RNA Ap1 (motif I, lanes 1-3) were incubated in the presence of 40 pMols each of recombinant GST bov-rPrP25-242 (rPrP c ) (lane 2) and GST bov- rPrP93-242
- Figure 7 Mapping of the RNA aptamer - PrP interaction site of hamster and calf
- A 4 pMols of labeled RNA aptamer motif I (lanes 1 -9) and (B) 4 pMols of labelled RNA aptamer motif II (lanes 1-9) were incubated in the presence of 40 pMol each of GST::rPrP23-231 (rPrP c ) (lanes 8), GST::rPrP90-231 (rPrP27-30) (lanes 9) from hamster and 20 pMol each of GST::P23-52 (lanes 2), GST::P55-93 (lanes 3).
- Cycles 1-9 5'[ ⁇ - 32 P]-ATP labeled (1. Cycle) or [ ⁇ - 3 P]-UTP labeled (Cycles 2-10) RNA M111.1 (Famulok, 1994) (6,8 nMol (first), 1.82 nMol (2nd), 914 pMol (3rd), 665 pMol (4th), 2.07 nMol (5th), 831 pMol (6th), 2.7 nMol (7th), 1.94 nMol (8th and 9th cycle) was incubated in the presence of immobilized GST (185 pMol) synthesized in the Baculovirus system (Weiss et al., 1995) in binding buffer comprised of 8 mM Na 2 HPO 4 , 0.87 mM KH 2 PO 4 , 136 mM NaCl, 112.6 mM KCI, 2 mM DTT and 2 mM MgCI 2 (Fig.
- Cycle 9 to 11 Selected RNA (40 pMol in the 9th; 4 pMol each in the 10th and 11th cycle) was 5' labeled and incubated with soluble GST.:rPrP c 23-231 (Weiss et al.,
- RNA GST::PrP c 23-231 complex was excised and extracted by employing an
- Cycle 1-11 50 % each of the extracted RNA was subjected to a reverse transcription reaction according to the Superscript reverse transcriptase kit (Gibco, BRL). 50 % of the resulting cDNA was amplified by PCR according to Saiki et al., 1988 using the primers shown in Figure 2B. 50 % of the amplified cDNA was in vitro transcribed as described (Weiss et al., 1992).
- RNA and protein were incubated as described above and the reaction mixture loaded on a 0.7 % native agarose gel as described (Weiss et al.,
- the technical features of RNA pool M1 1 1 1 are the following
- RNA pool M111 1 A schematic view of RNA pool M111 1 is shown in Fig 2
- the nucleotide sequence 5'-CCGAATTCTAATACGACTCACTATA (nucleotides 1 to 25 of SEQ ID NO 19) of the fixed region 1 only belongs to the DNA pool since it is not transcribed
- RNA binding After 9 rounds of selection 7 2 % of the selected RNA bound to GST rPrP c 23-231 immobilized on glutathione-sepharose 4B (Table 1 and Fig 3) The percentage of RNA-binding was determined as follows: Radioactivity associated with GST::rPrP c beads after removal of supernatant was set to 100 %. Radioactivity retained after four washing steps represents the percentage of the RNA binding.
- RNA:GST GST::rPrP c (RNA to
- a binding assay employing soluble GST, GST::PrP c 23-231 and GST::rPrP27-30 revealed that 2 % of the enriched RNA from cycle 9 bound to GST::PrP c 23-231 whereas only 1.1 % bound to GST::rPrP27-30 and GST (Fig. 4 A). This result indicates that -5 % of the RNA bound to the matrix, i.e. glutathione-sepharose 4B. After 6 rounds of selection only 1 % of the RNA bound to immobilized GST::PrP c 23- 231 and 0.7 % to GST (Fig. 4A).
- a gel retardation assay with RNA isolated after 9 cycles of selection confirms that about 2 % of the RNA bound to GST::PrP c 23-231 at a molar ratio of 10:1 (protein:RNA) (Fig. 4B, panel a, lane 6), whereas no binding occurs under identical conditions in the case of GST::rPrP27-30 (lane 9) and GST (lane 3).
- RNA aptamer able to distinguish between PrP c 23-231 and rPrP27-30 overcomes the problem that it is not possible to produce poly- and monoclonal PrP antibodies which recognize specifically only one PrP isoform (Groschup et al , 1984 and ref therein) and provides a suitable tool for a reliable diagnostic of transmissible spongiform encephalopathy
- RNA molecules identified after 11 cycles of amplification and selection were reversed transcribed into cDNA and amplified by PCR (Sambrook et al , 1989)
- the obtained cDNA was restricted with EcoRI and BamHI, subcloned into pGEM-3-Zf(-) and the sequence of 20 different cDNA clones pGEM-Ap 1 to 20 determined according to Sanger et al (1977)
- Sequences of 14 RNA molecules identified are depicted in Figure 5 (SEQ ID NO: 1 to 14)
- the obtained monoclonal RNAs revealed sequences which may contain G-quartet motifs.
- Three classes of G-quartet motifs Table II, Fig.
- RNA molecules could be identified with more than one monoclonal RNA.
- 30 % of the sequenced DNA molecules encode for unique RNA molecules which may also contain G-quartets (Fig. 5D), 30 % of the selected RNA aptamers did not contain any G-quartet motif (Fig. 5E).
- Table II Distribution of selected RNA aptamers.
- G-tetrad motifs had already been identified in several other in-vitro selected nucleic acid molecules (see e g. Bock et al , 1992, Wang et al., 1993, Macaya et al., 1993, Lauhon and Szostak, 1995, Huizenga and Szostak, 1995, Harada and Frankei, 1995) and appear to represent an important feature in nucleic acid molecules which bind to a ligand with high specificity.
- G-quartets have been suggested for telomeric DNA sequences in species such as Tetrahymena (Sundquist and Klug, 1989; Williamson et al., 1989; for review: Williamson, 1993). Guanine rich sequences which could form G-quartets were found in immunoglobulin switch regions, gene promotors and in chromosomal telomers which are thought to bring the four homologous chromatids together during meiosis and prevent the DNA from degradation (Sen and Gilbert, 1988). G-quartets have also been discussed to play a role in the dimerization process of retroviral genomic RNA (Weiss et al., 1993), a prerequisite for the generation of infectious virions.
- RNA aptamers selected against the prion protein could contain three G-quartets stacked upon each other (Fig. 6) to form two eight-coordinate chelation cages.
- Alkali-metal ions such as potassium located within the axial channel are able to complex four oxygens of the upper and four oxygens of the lower G-quartet. Because of the very compact structure G-tetrads are very stable and unusual RNAse resistant.
- RNA aptamers harboring G-quartet motif I and II bind specifically to rPrP23-231 (rPrP c ) from hamster and rPrP25-242 (rPrP c ) from calf
- RNA aptamers representing motif I (Ap1 , Figure 6 A, B) and II (Ap2, Figure 6C, D) interact specifically with rPrP23-231 (rPrP c ) from Syrian golden hamster ( Figure 6 A, C; lanes 2) and rPrP25-242 (rPrP c ) from cattle ( Figure 6 B, D, lanes 2) both fused to GST Prion proteins from hamster and cattle reveal a sequence homology of 88% Bovine PrP was synthesized in insect cells infected with a recombinant baculovirus containing bovine prn-p cDNA (Yoshimoto et al , 1992) Binding of the RNA aptamers to bovine PrP was investigated to prove whether the aptamers are suitable for the development of a BSE diagonostic tool Both aptamers do not bind to the recombinant GST fused prion proteins rPrP90-231 (rPrP
- an aptamer was constructed consisting of 60 nucleotides on the basis of an aptamer comprising motif I as shown in Figure 5, which, however, lacked the primer binding sites as well as 14 nucleotides of the randomized region
- This 60-mer exactly corresponds to a part of one of the aptamers displaying the motif I as depicted in Figure 6A/B and displayed the same binding characteristics as the full- length aptamer
- the sequence of this 60mer is depicted in SEQ ID NO 18
- This molecule was isolated by the following procedure By using two appropriate primers, DNA containing the 60 nucleotides encoding the RNA motif I ( Figure 5A, #ll, SEQ ID NO.
- This 60mer was also used for the determination of the equilibrium binding constants.
- 4 pMol of 5' ⁇ - 3 P-ATP labelled and ⁇ - 32 P-UTP labelled RNA aptamer motif I (SEQ ID NO: 18) was incubated in the presence of 0, 4, 20, 28, 40, 60, 80, 108 pMol of GST::rPrP23-231 for 60 mm at 37°C under assay conditions as described above.
- RNA protein complexes have been analyzed by an gel retardation assay (Weiss et al., 1992). Gel was fixed by 5% TCA, dried and subjected to autoradiography for 12 hours.
- R RNA aptamer motif I (60mer)
- P GST..rPrP23-231 (GST..rPrP c ),
- K D equilibrium binding constant
- Prion peptides P25-92 and P93-12O (Fig- 7C, lane 3) from bovine PrP have been synthesized to map the interaction site of bovine PrP c to RNA aptamer motif II. Only P25-92 (Fig- 7C, lane 2) did bind to RNA aptamer motif II (Ap2) demonstrating that it is the amino terminus of the bovine prion protein which is recognized by the aptamer. Hamster peptide P23-89 (Fi - 7C, lane 4) did also interact with aptamer Ap2 confirming the interaction of the amino terminus of the hamster prion protein with aptamer motif II. Cited References
- the major polypeptide of scrapie-associated fibrils has the same size, charge distribution and N-terminal protein sequence as predicted for the normal brain protein (PrP) EMBO J 5 (1986), 2591 -2597
- Prusiner S B Novel proteinaceous infectious particles cause scrapie Science 216 (1982), 136-144
- Prusiner, S B McKmley, M P, Bowman, K A , Bolton, D C, Bendheim, P E , Groth, D F and Glenner, G G Scrapie prions aggregate to form amyloid-like birefringent rods Ce// 35 (1983), 349-358
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- ANTI-SENSE NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: CACUGCUACC UUAGAGUAGG AGCGGGACGA GGGGUUGUUG GGACGUGGGU AUGAUCCAUA 60 CAUUAGGAAG CUGGUGAGCU GGCACC 86
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA”
- HYPOTHETICAL YES
- ANTI-SENSE NO
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- MOLECULE TYPE other nucleic acid
- DESCRIPTION: /desc "RNA"
- ANTI-SENSE NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: CCGAATTCTA ATACGACTCA CTATAGGAGC TCAGCCTTCA CTGC 44
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69618614T DE69618614T2 (en) | 1995-10-26 | 1996-10-25 | NUCLEIC ACID MOLECULES WITH THE ABILITY TO DIFFERENT PrPc AND PrPSc-PRIONPROTEIN ISO FORMS AND METHOD FOR THE PRODUCTION THEREOF |
JP9516298A JPH11514874A (en) | 1995-10-26 | 1996-10-25 | Nucleic acid molecules capable of distinguishing between PrP iso-C and PrP-SC of prion protein and methods for producing them |
US09/051,962 US6426409B1 (en) | 1995-10-26 | 1996-10-25 | Nucleic acid molecules that bind prion proteins and processes for the production thereof |
DK96937257T DK0862653T3 (en) | 1995-10-26 | 1996-10-25 | Nucleic acid molecules capable of distinguishing between the PrPc and PrPSc isoforms of prion proteins and processes for their preparation |
EP96937257A EP0862653B1 (en) | 1995-10-26 | 1996-10-25 | NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION |
AT96937257T ATE212065T1 (en) | 1995-10-26 | 1996-10-25 | NUCLEIC ACID MOLECULES WITH THE CAPABILITY OF DISTINCTING PRPC AND PRPSC PRION PROTEIN ISOFORMS AND METHODS FOR THE PRODUCTION THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95116890.5 | 1995-10-26 | ||
EP95116890 | 1995-10-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997015685A1 true WO1997015685A1 (en) | 1997-05-01 |
Family
ID=8219750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1996/004671 WO1997015685A1 (en) | 1995-10-26 | 1996-10-25 | NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION |
Country Status (8)
Country | Link |
---|---|
US (2) | US6426409B1 (en) |
EP (1) | EP0862653B1 (en) |
JP (1) | JPH11514874A (en) |
AT (1) | ATE212065T1 (en) |
DE (1) | DE69618614T2 (en) |
DK (1) | DK0862653T3 (en) |
ES (1) | ES2171231T3 (en) |
WO (1) | WO1997015685A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999015903A1 (en) * | 1997-09-19 | 1999-04-01 | Evotec Biosystems Ag | Method for measuring the association of substructures of pathological protein deposits |
DE19916417A1 (en) * | 1999-04-01 | 2000-10-19 | Schering Ag | New amyloid-specific aptamer, useful for diagnosis and/or treatment of e.g. Alzheimer's disease, is stabilized against nucleases |
WO2000073501A2 (en) * | 1999-06-01 | 2000-12-07 | LASMÉZAS, Corinne, Ida | Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
FR2808278A1 (en) * | 2000-04-28 | 2001-11-02 | Inst Nat Sante Rech Med | PRION PROTEINS AND THEIR USES |
WO2001088123A1 (en) * | 2000-05-18 | 2001-11-22 | Isis Innovation Limited | Ligands specific for an isoform of the prion protein |
WO2002097049A2 (en) * | 2001-05-31 | 2002-12-05 | Q-Rna | Compositions and methods for binding agglomeration proteins |
EP1497459A2 (en) * | 2002-04-15 | 2005-01-19 | Q-RNA, Inc. | A device and methods for concentrating prion protein isoforms |
EP1570235A2 (en) * | 2002-08-15 | 2005-09-07 | Q-RNA, Inc. | Compositions and methods used for identifying factors required for the agglomeration of proteins |
US7232807B2 (en) | 2001-05-31 | 2007-06-19 | Oligomerix, Inc. | Compositions and methods for binding agglomeration proteins |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002034935A2 (en) * | 2000-10-27 | 2002-05-02 | Research Development Foundation | In vitro selection of signaling aptamers |
US20050261486A1 (en) * | 2001-05-31 | 2005-11-24 | Q-Rna | Compositions and methods for binding agglomeration proteins |
US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
US20040086924A1 (en) * | 2001-10-26 | 2004-05-06 | Research Development Foundation | In vitro selection of signaling aptamers |
AU2003267785C1 (en) * | 2002-09-13 | 2009-12-24 | Replicor, Inc. | Non-sequence complementary antiviral oligonucleotides |
US20050196382A1 (en) * | 2002-09-13 | 2005-09-08 | Replicor, Inc. | Antiviral oligonucleotides targeting viral families |
US7399603B2 (en) * | 2002-12-19 | 2008-07-15 | Ortho-Clinical Diagnostics, Inc. | Antibodies for discrimination of prions |
EP1445615A1 (en) * | 2003-02-10 | 2004-08-11 | Ortho-Clinical Diagnostics, Inc. | Method for discrimination between infectious and noninfectious prions |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
CA2538245A1 (en) * | 2003-09-11 | 2005-03-24 | Replicor Inc. | Oligonucleotides targeting prion diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020242A1 (en) * | 1992-03-30 | 1993-10-14 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4917998A (en) * | 1986-05-06 | 1990-04-17 | Epitope, Inc. | Method of detecting AIDS virus infection |
US5567588A (en) * | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
US5270163A (en) * | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
US5582981A (en) * | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
-
1996
- 1996-10-25 WO PCT/EP1996/004671 patent/WO1997015685A1/en active IP Right Grant
- 1996-10-25 AT AT96937257T patent/ATE212065T1/en not_active IP Right Cessation
- 1996-10-25 ES ES96937257T patent/ES2171231T3/en not_active Expired - Lifetime
- 1996-10-25 DK DK96937257T patent/DK0862653T3/en active
- 1996-10-25 DE DE69618614T patent/DE69618614T2/en not_active Expired - Fee Related
- 1996-10-25 EP EP96937257A patent/EP0862653B1/en not_active Expired - Lifetime
- 1996-10-25 JP JP9516298A patent/JPH11514874A/en not_active Ceased
- 1996-10-25 US US09/051,962 patent/US6426409B1/en not_active Expired - Fee Related
-
2002
- 2002-07-03 US US10/187,783 patent/US20030119019A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020242A1 (en) * | 1992-03-30 | 1993-10-14 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
Non-Patent Citations (5)
Title |
---|
FAMULOK M: "Molecular regognition of amino acids by RNA-Aptemers: An L-citrulline binding RNA motif and its evolution into an L-argenine binder", J. AM. CHEM. SOC., vol. 116, March 1994 (1994-03-01), pages 1698 - 1706, XP000644374 * |
GOLD L: "Oligonucleotides as research, diagnostic, and therapeutic agents", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 23, June 1995 (1995-06-01), pages 13581 - 84, XP002025263 * |
KLUG S ET AL: "All you wanted to know about SELEX", MOLECULAR BIOLOGY REPORTS, vol. 20, no. 2, 1994, pages 97 - 107, XP000617781 * |
SCHREUDER B. E.: "General aspects of transmissible spongiform encephalopathies and hypotheses about the agents", VETINARY QUARTERLY, vol. 15, no. 4, December 1993 (1993-12-01), pages 167 - 74, XP000617784 * |
WEISS S ET AL: "Over expression of active golden hampster prion protein PrPc as a glutathionine S-transferase fusion in heterologous systems", JOURNAL OF VIROLOGY, vol. 69, no. 8, August 1995 (1995-08-01), pages 4776 - 83, XP000644456 * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6498017B2 (en) | 1907-11-28 | 2002-12-24 | Evotec Biosystems Ag | Method for measuring the association of substructures of pathological protein depositions |
WO1999015903A1 (en) * | 1997-09-19 | 1999-04-01 | Evotec Biosystems Ag | Method for measuring the association of substructures of pathological protein deposits |
DE19916417A1 (en) * | 1999-04-01 | 2000-10-19 | Schering Ag | New amyloid-specific aptamer, useful for diagnosis and/or treatment of e.g. Alzheimer's disease, is stabilized against nucleases |
WO2000073501A2 (en) * | 1999-06-01 | 2000-12-07 | LASMÉZAS, Corinne, Ida | Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
WO2000073501A3 (en) * | 1999-06-01 | 2001-03-08 | Lasmezas Corinne Ida | Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
DE19925073A1 (en) * | 1999-06-01 | 2001-03-15 | Stefan Weiss | Nucleic acid molecules with specific recognition of native PrP · S ·· c ·, production and use |
DE19925073C2 (en) * | 1999-06-01 | 2001-07-19 | Stefan Weiss | Nucleic acid molecules with specific recognition of native PrP · S ·· c ·, production and use |
US7371833B1 (en) * | 1999-06-01 | 2008-05-13 | Stefan Weiss | Nucleic acid molecules with specific recognition of native PrPSc, production and use |
FR2808278A1 (en) * | 2000-04-28 | 2001-11-02 | Inst Nat Sante Rech Med | PRION PROTEINS AND THEIR USES |
WO2001083747A2 (en) * | 2000-04-28 | 2001-11-08 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Prion proteins and their uses |
WO2001083747A3 (en) * | 2000-04-28 | 2002-02-28 | Inst Nat Sante Rech Med | Prion proteins and their uses |
WO2001088123A1 (en) * | 2000-05-18 | 2001-11-22 | Isis Innovation Limited | Ligands specific for an isoform of the prion protein |
WO2002097049A3 (en) * | 2001-05-31 | 2003-09-25 | Q Rna | Compositions and methods for binding agglomeration proteins |
US7232807B2 (en) | 2001-05-31 | 2007-06-19 | Oligomerix, Inc. | Compositions and methods for binding agglomeration proteins |
WO2002097049A2 (en) * | 2001-05-31 | 2002-12-05 | Q-Rna | Compositions and methods for binding agglomeration proteins |
EP1497459A2 (en) * | 2002-04-15 | 2005-01-19 | Q-RNA, Inc. | A device and methods for concentrating prion protein isoforms |
EP1497459A4 (en) * | 2002-04-15 | 2005-09-07 | Q Rna Inc | A device and methods for concentrating prion protein isoforms |
EP1570235A2 (en) * | 2002-08-15 | 2005-09-07 | Q-RNA, Inc. | Compositions and methods used for identifying factors required for the agglomeration of proteins |
EP1570235A4 (en) * | 2002-08-15 | 2008-03-05 | Q Rna Inc | Compositions and methods used for identifying factors required for the agglomeration of proteins |
Also Published As
Publication number | Publication date |
---|---|
DE69618614T2 (en) | 2002-09-12 |
ES2171231T3 (en) | 2002-09-01 |
US20030119019A1 (en) | 2003-06-26 |
EP0862653B1 (en) | 2002-01-16 |
ATE212065T1 (en) | 2002-02-15 |
DK0862653T3 (en) | 2002-03-11 |
US6426409B1 (en) | 2002-07-30 |
DE69618614D1 (en) | 2002-02-21 |
JPH11514874A (en) | 1999-12-21 |
EP0862653A1 (en) | 1998-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0862653B1 (en) | NUCLEIC ACID MOLECULES CAPABLE OF DISTINGUISHING THE ISOFORMS PrPc AND PrPSc OF PRION PROTEINS AND PROCESSES FOR THEIR PRODUCTION | |
Klußmann et al. | Mirror-image RNA that binds D-adenosine | |
AU2008275917B2 (en) | Multiplexed analyses of test samples | |
CA2924987C (en) | Multiaptamer target detection | |
JP2003501050A (en) | Nucleic acid molecule specifically recognizing native PrPSC, production and use | |
Oliveira et al. | Improving aptamer performance with nucleic acid mimics: de novo and post-SELEX approaches | |
King et al. | Thioaptamer interactions with prion proteins: sequence-specific and non-specific binding sites | |
US7232807B2 (en) | Compositions and methods for binding agglomeration proteins | |
US20030162225A1 (en) | Ligands specific for an isoform of the prion protein | |
Lato et al. | Screening chemical libraries for nucleic-acid-binding drugs by in vitro selection: a test case with lividomycin | |
US20050261486A1 (en) | Compositions and methods for binding agglomeration proteins | |
JP4671148B2 (en) | Nucleic acid molecules that specifically bind to prion proteins | |
JP5191028B2 (en) | RNA aptamer that binds to fibrils derived from abnormal prion protein | |
AU2013203386B2 (en) | Method for generating aptamers with improved off-rates | |
AU2015261546A1 (en) | Multiplexed analyses of test samples | |
JP2004520080A (en) | Compositions and methods for binding to coagulated proteins | |
AU2013203360B2 (en) | Multiplexed analyses of test samples | |
Anderson | Non-nucleosidic modifications in the selection of thrombin-binding aptamers | |
Bhosale et al. | Oligonucleotide based therapeutics: aptamers | |
Manimala | SELEX: a tool to study the sequence specific molecular recognition of single stranded nucleic acids | |
Bennett | Mapping the Interactions within RNase Mrp | |
Zhao | 2D layout of bead based thioaptamer/aptamer selection platform for therapeutics and diagnostics | |
WO2004110243A2 (en) | COMPOSITIONS AND METHODS FOR ENHANCING THE IDENTIFICATION OF PRION PROTEIN PRPsc | |
STREHLITZ | REGINA STOLTENBURG, CHRISTINE REINEMANN AND |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL JP LT LV RO SI US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 516298 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996937257 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1996937257 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09051962 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996937257 Country of ref document: EP |